LFLorraine Flet-Berliac

Lorraine Flet-Berliac

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lorraine Flet-Berliac has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Lépine

    Pediatric Neurology Department, Assistance Publique des Hôpitaux de Marseille, Hôpital Universitaire, Marseille

    2 shared publications
  • Anca Florea

    Pediatric Neurology Departement, Assistance Publique des Hôpitaux de Paris, Hôpitaux Universitaires Paris‐Saclay, Bicêtre Hospital, and Paris‐Saclay University Le Kremlin‐Bicêtre France

    1 shared publication
  • Bastien Joubert

    French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France

    1 shared publication
  • Carole Leroy

    Université Paris-Saclay, CEA, INSERM Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT)

    1 shared publication
  • Elodie Lametery

    Department of Pediatrics Neurology, Grenoble University Hospital, France

    1 shared publication
  • Emmanuel Cheuret

    Pediatric Neurology Department Purpan University Hospital Toulouse France

    1 shared publication

Latest Publications

  • Open Access

    Long-Term Clinical and Biological Prognostic Factors of Anti-NMDA Receptor Encephalitis in Children

    by Maxime Mazowiecki, Lorraine Flet-Berliac, Julia Roux, Anne Lépine, Pascale Chretien, Salima Hacein-Bey-Abina, Laetitia Giorgi, Frederic Villega, Emmanuel Cheuret, Marie Benaiteau, et al.

    Anti-NMDAR encephalitis (NMDARE) is a severe neurologic condition, and recently, the NMDAR Encephalitis One-Year Functional Status (NEOS) score has emerged as a 1-year prognostic tool. This study aimed to evaluate NEOS score and biomarker (neurofilament light chains [NfL], total-Tau protein, glial fibrillary acidic protein, and serum cytokines) correlation with modified Rankin Scale (mRS), cognitive impairment, and clinical recovery in pediatric NMDARE over 2 years. In this French multicenter observational study, 104 pediatric patients with NMDARE were followed for a minimum of 2 years. Clinical data and serum/plasma samples were collected. Biomarker levels, measured using electroluminescence mesoscale discovery (MSD) S-PLEX, were compared between patients and controls and assessed for correlations with disease activity, mRS, cognitive/language impairment, and recovery status at 2 years. At a median follow-up of 39.5 months, 68 percent of patients had unfavorable recovery and 54% had significant cognitive impairment. Both outcomes were strongly associated with younger age at diagnosis (OR 6.10 [1.91-27.3] p < 0.01 and 5.69 [1.46-27.7] p = 0.02, respectively). A higher NEOS score was significantly correlated with increased cognitive impairment (OR 2.53 [1.52-4.21], p < 0.001), higher mRS scores (OR 2.12 [1.34-3.57], p < 0.01), and unfavorable recovery at 2 years (OR 2.00 [1.30-3.06], p = 0.015). Elevated NfL levels were significantly associated with unfavorable recovery (OR 3.62 [1.29-10.9] p = 0.012) and severe cognitive impairment (OR 3.77 [1.38-10.9] p = 0.012) at 2 years. The combined area under the curve (AUC) for NfL and NEOS was significantly higher than the AUCs of NEOS and NfL alone (p = 0.01). The NEOS score strongly predicts long-term outcomes in NMDARE, with its predictive value extending beyond the first-year mR prediction. NfL levels at disease onset seem to improve accuracy in predicting poor outcomes, providing valuable information for treatment decisions and future clinical trials.


  • Long‐term outcome of paediatric anti‐N‐methyl‐D‐aspartate receptor encephalitis

    by Lorraine Flet‐Berliac, Nicolas Tchitchek, Anne Lépine, Anca Florea, Hélène Maurey, Pascale Chrétien, Salima Hacein‐Bey‐Abina, Frederic Villega, Emmanuel Cheuret, Véronique Rogemond, et al.

    Aim: To study long‐term clinical and cognitive outcomes of patients with anti‐N‐methyl‐d‐aspartate receptor encephalitis (NMDAR‐E), an acute autoimmune neurological disease with severe acute presentations.Method: In this French multicentre retrospective observational cohort study, patients no older than 18 years with a follow‐up of at least 2 years were included. Data from clinical and cognitive assessments were collected.Results: Eighty‐one patients were included (57 females, 24 males; median age 10 years 7 months [range 1–18 years], median follow‐up 40 months [range 25–53 months]). At last follow‐up, 35 patients (45%) had cognitive impairment, 48 (70%) had academic difficulties, and 65 (92%) needed rehabilitation. Seventy‐one patients (88%) had a modified Rankin Scale score of no more than 2. A higher number of symptoms at diagnosis was associated with cognitive impairment (p = 0.01), while an abnormal electroencephalogram at diagnosis increased the risk of academic difficulties (p = 0.03).Interpretation: Although most children with NMDAR‐E seemed to recover from motor disabilities, more than 45% had cognitive and academic difficulties. The initial severity of symptoms seems to have an impact on cognition and academic performances.What this paper adds: Forty‐five per cent of patients had cognitive impairment at ≥2 years diagnosis of anti‐N‐methyl‐d‐aspartate receptor encephalitis (NMDAR‐E). Seventy per cent of patients had academic difficulties at ≥2 years diagnosis of NMDAR‐E. Ninety‐two per cent of patients needed rehabilitative care at ≥2 years diagnosis of NMDAR‐E. A high number of symptoms at diagnosis were associated with cognitive impairment.